Skye Bioscience insider sells 148,079 shares

A separate partnership, 5AM Ventures VII, L.P., reported an indirect holding of 981,269 shares on September 22, 2026.

Rhea-AI Filing Summary

Skye Bioscience, Inc. director and 10% owner Andrew J. Schwab reported sales of common shares held by 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P., totaling 148,079 shares on September 22 and 23, 2026. The September 22 sales were reported at $1.65 per share; the September 23 sales were reported at a weighted average of $1.61 per share, with sale prices ranging from $1.60 to $1.77.

Insider Trade Summary

Net Seller: 148,079 shares

Net Sell 5 txns

Insider Schwab Andrew J.

Role Director, 10% Owner

Sold 148,079 shs ($240K)

Type	Security	Shares	Price	Value
Sale	Common Stock F3, F1	114,851	$1.61	$185K
Sale	Common Stock F3, F2	4,528	$1.61	$7K
Sale	Common Stock F1	27,612	$1.65	$46K
Sale	Common Stock F2	1,088	$1.65	$2K
holding	Common Stock F4	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Indirect, By 5AM Ventures II, L.P.); Common Stock — 0 shares (Indirect, By 5AM Co-Investors II, L.P.); Common Stock — 981,269 shares (Indirect, By 5AM Ventures VII, L.P.)

Footnotes (4)

1. F1. The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
2. F2. The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
3. F3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
4. F4. The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Key Figures

Shares sold across reported transactions: 148,079 shares Shares sold: 114,851 shares Shares sold: 4,528 shares +3 more

6 metrics

Shares sold across reported transactions 148,079 shares September 22 and 23, 2026

Shares sold 114,851 shares Held by 5AM Ventures II, L.P.; September 23, 2026; reported at $1.61 per share

Shares sold 4,528 shares Held by 5AM Co-Investors II, L.P.; September 23, 2026; reported at $1.61 per share

Shares sold 27,612 shares Held by 5AM Ventures II, L.P.; September 22, 2026; reported at $1.65 per share

Shares sold 1,088 shares Held by 5AM Co-Investors II, L.P.; September 22, 2026; reported at $1.65 per share

Reported indirect holding 981,269 shares 5AM Ventures VII, L.P.; September 22, 2026

Key Terms

weighted average price, beneficial ownership, pecuniary interest, shared voting and investment power, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership regulatory

"disclaims beneficial ownership of such securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein"

shared voting and investment power regulatory

"may be deemed to have shared voting and investment power"

sole general partner financial

"is the sole general partner of Ventures II"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SKYE shares were sold, and at what prices?

5AM Ventures II, L.P. and 5AM Co-Investors II, L.P. reported sales totaling 148,079 shares on September 22 and 23, 2026. The September 22 sales were reported at $1.65 per share. The September 23 sales were reported at a weighted average of $1.61 per share, with prices ranging from $1.60 to $1.77 inclusive.

Were the SKYE sales under a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported for these transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 04:32 PM Accepted by SEC EDGAR 09/24/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schwab Andrew J.

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CALIFORNIA 94111

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2026		S		27,612	D	$1.65	114,851	I	By 5AM Ventures II, L.P.(1)
Common Stock	09/22/2026		S		1,088	D	$1.65	4,528	I	By 5AM Co-Investors II, L.P.(2)
Common Stock	09/23/2026		S		114,851	D	$1.61(3)	0	I	By 5AM Ventures II, L.P.(1)
Common Stock	09/23/2026		S		4,528	D	$1.61(3)	0	I	By 5AM Co-Investors II, L.P.(2)
Common Stock								981,269	I	By 5AM Ventures VII, L.P.(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

2. The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

4. The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Andrew J. Schwab	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)